Clinical Edge Journal Scan

Efficacy of colonoscopy for preventing CRC remains unaffected by location


 

Key clinical point: Colonoscopy screening prevents both distal and proximal colorectal cancer (CRC) with similar efficacy.

Major finding: After 11 years of follow-up, the colonoscopy screening vs no screening group showed an adjusted CRC risk of 1.62% vs 2.38%, respectively, with the adjusted relative risk (aRR) being 0.68 (95% CI 0.63-0.73). The aRR for distal vs proximal CRC was 0.67 (95% CI 0.62-0.73) vs 0.70 (95% CI 0.63-0.79), respectively.

Study details: This study analyzed the observational data of 307,158 participants from a German claims database who were 55-69 years old, at an average risk for CRC, and did (n = 198,389) or did not (n = 117,399) undergo colonoscopy screening.

Disclosures: This study was supported by intramural funding from the Leibniz Institute for Prevention Research and Epidemiology–BIPS, Germany. The authors declared no conflicts of interest.

Source: Braitmaier M et al. Screening colonoscopy similarly prevented distal and proximal colorectal cancer: a prospective study among 55–69-year-olds J Clin Epidemiol. 2022;149:118-126 (Jun 6). Doi: 10.1016/j.jclinepi.2022.05.024

Recommended Reading

Pregnancy, breastfeeding, and more linked to lower CRC risk
MDedge Hematology and Oncology
Liver cancer risk persists after direct-acting antiviral treatment for HCV
MDedge Hematology and Oncology
U.S. hot, cold spots of young-onset CRC may help target interventions
MDedge Hematology and Oncology
Marital status plays modest role in gastric cancer overall survival
MDedge Hematology and Oncology
Life-threatening adverse events in liver cancer less frequent with ICI therapy
MDedge Hematology and Oncology
Barrett’s esophagus: AGA screening update ‘goes above and beyond’
MDedge Hematology and Oncology
Stage II colon cancer: ctDNA-guided approach reduces adjuvant chemotherapy use without compromising recurrence risk
MDedge Hematology and Oncology
Link between Western diet, intestinal microbiota, and CRC: Findings from 2 U.S. cohort studies
MDedge Hematology and Oncology
Stage II/III CRC: 3-month oxaliplatin with 6-month fluoropyrimidine, a promising adjuvant treatment
MDedge Hematology and Oncology
FOLFIRI-bevacizumab tops FOLFIRI-aflibercept in treating metastatic CRC after FOLFOX-bevacizumab failure
MDedge Hematology and Oncology